ERBB2 and breast carcinoma: A recent randomized trial by Guglin et al. demonstrated that, in a population of women with HER2-positive breast cancer treated with trastuzumab, both lisinopril and carvedilol could prevent trastuzumab cardiotoxicity and patients treated with these drugs experienced fewer trastuzumab interruptions [101].